"By now the studies are irrefutable" and the field experiments "are demonstrating the greater effectiveness of heterologous vaccination".
So the president of Aifa, Giorgio Palù, on Rai Radio1.
"They are about hundreds of people this is true", Palù emphasizes, but they are published in pre-print by various European universities "and show that using two different formulations, the immune system is better stimulated because both intrinsic and innate immunity are activated. adaptive "and" even those fears that there were early data on greater reactogenicity are all disappearing ".
And on the reactogenicity Palù, recalling the studies of various Institutes, from that of the University of Hanover to the University of Oxford, then also of Berlin and Spain, explains: "There is no and if in some cases there is, it is very short duration. So there is no problem. " Science, says Palù referring to the nations that "before us decided to abandon vaccines to adenoviral vectors" and that have adopted a heterologous administration, "acquires studies from time to time, therefore, he specifies, we must not think about contradictions. scientific truth manifests itself in the field. So I remember that it is true that it is an on-label vaccination that is authorized by Fda and Ema, with two identical vaccinesbut if we realize that two different vaccines work better, the regulatory bodies can intervene ".